<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-10-20" updated="2020-01-02">
  <drugbank-id primary="true">DB11660</drugbank-id>
  <name>Latanoprostene bunod</name>
  <description>Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure.&#13;
&#13;
As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for proposed tissue/cell relaxation effects.&#13;
&#13;
In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost.</description>
  <cas-number>860005-21-6</cas-number>
  <unii>I6393O0922</unii>
  <average-mass>507.624</average-mass>
  <monoisotopic-mass>507.283217284</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31280</ref-id>
        <pubmed-id>27457469</pubmed-id>
        <citation>Kawase K, Vittitow JL, Weinreb RN, Araie M: Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. Adv Ther. 2016 Sep;33(9):1612-27. doi: 10.1007/s12325-016-0385-7. Epub 2016 Jul 25.</citation>
      </article>
      <article>
        <ref-id>A31282</ref-id>
        <pubmed-id>27210275</pubmed-id>
        <citation>Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN: Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Am J Ophthalmol. 2016 Aug;168:250-259. doi: 10.1016/j.ajo.2016.05.012. Epub 2016  May 20.</citation>
      </article>
      <article>
        <ref-id>A31283</ref-id>
        <pubmed-id>26875002</pubmed-id>
        <citation>Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J: Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016 May;123(5):965-73. doi: 10.1016/j.ophtha.2016.01.019. Epub 2016 Feb 11.</citation>
      </article>
      <article>
        <ref-id>A31284</ref-id>
        <pubmed-id>28234563</pubmed-id>
        <citation>Kaufman PL: Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother. 2017 Mar;18(4):433-444. doi: 10.1080/14656566.2017.1293654. Epub 2017 Feb 20.</citation>
      </article>
      <article>
        <ref-id>A31285</ref-id>
        <pubmed-id>27799730</pubmed-id>
        <citation>Garcia GA, Ngai P, Mosaed S, Lin KY: Critical evaluation of latanoprostene bunod in the treatment of glaucoma. Clin Ophthalmol. 2016 Oct 18;10:2035-2050. eCollection 2016.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Latanoprostene bunod opthalmic solution is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension [FDA Label].</indication>
  <pharmacodynamics>Upon applying an appropriate dose of latanoprost bunod, reduction in intraocular pressure begins approximately 1 to 3 hours later with a maximum intraocular pressure reduction effect demonstrated after 11 to 13 hours [FDA Label].</pharmacodynamics>
  <mechanism-of-action>Open-angle glaucoma (OAG) is a medical condition that is associated with progressive visual field damage and the loss of vision [A31280].&#13;
&#13;
Occular hypertension (OHT) is considered a key risk factor for OAG and reducing intraocular pressure (IOP) and being able to maintain unique and appropriate target IOPs for various different patients having OHT can delay or prevent the onset of primary OAG or slow the disease progression of established glaucoma [A31280].&#13;
&#13;
Ordinary physiological IOP results from aqueous humor produced by the ocular ciliary body and its outflow through a) the trabecular meshwork (TM) and Schlemm's canal (SC) in what is called the conventional pathway, and b) the uveoscleral pathway via the ciliary muscle/choroid/sclera in what is refered to as the unconventional pathway [A31284].&#13;
&#13;
In patients with OHT or OAG there is increased resistance to aqueous humor outflow by way of the TM/SC pathway, which causes increased IOP. This increase in IOP is believed to be the cause of mechanical stress on the posterior structures of the eye which can result in the dysfunction of optic nerve fibers and the destruction of retinal ganglion cells - all of which ultimately contributes to vision loss [A31284].&#13;
&#13;
As there is no cure for glaucoma, therapeutic management is predominantly focused on minimizing disease progression and clinical sequelae via the reduction and maintainenance of appropriate target IOPs [A31284, A31280].&#13;
&#13;
Subsequently, latanoprostene bunod is thought to lower intraocular pressure via a dual mechanism of action since the medication is metabolized into two relevant moieties upon administration: (1) latanoprost acid, and (2) butanediol mononitrate [A31284, A31280, A31285].&#13;
 &#13;
As a prostaglandin F2-alpha analog [A31284], the latanoprost acid moiety operates as a selective PGF2-alpha (FP) receptor agonist [A31285]. Since FP receptors occur in the ciliary muscle, ciliary epithelium, and sclera the latanoprost acid moiety primarily acts in the uveoscleral pathway where it increases the expression of matrix metalloproteinases (MMPs) like MMP-1, -3, and -9 which promote the degradation of collagen types I, III, and IV in the longitudinal bundles of the ciliary musicle and surrounding sclera [A31285]. The resultant extracellular matrix remodeling of the ciliary muscle consequently produces reduced outflow resistance via increased permeability and increased aqueous humor outflow through the uveoscleral route [A31285].&#13;
&#13;
Conversely, the butanediol mononitrate undergoes further metabolism to NO and an inactive 1,4-butanediol moiety. As a gas that can freely diffuse across plasma membranes, it is proposed that the relaxing effect of NO to induce reductions in the cell volume and contractility of vascular smooth muscle like cells is dependant upon activation of the sGC/cGMP/PKG cascade pathway. NO released from butanediol mononitrate consequently enters the cells of the TM and inner wall of SC, causing decreases in myosin light chain-2 phosphorylation, increased phosphorylation of large-conductance calcium-activated potassium (BKCa) channels, and a subsequent efflux of potassium ions through such BKCa channels. All of these changes serve to decrease the cell contractility and volume, as well as to rearrange the actin cytoskeleton of the TM and SC cells. These biomechanical changes ultimately allow for enhanced conventional outflow of aqueous humor [A31285].</mechanism-of-action>
  <toxicity>There are no available human data for the use of latanoprost bunod during pregnancy to inform any drug associated risks. Use during pregnancy must consider whether any potential benefit to the patient will justify the risk presented to the fetus [FDA Label].&#13;
&#13;
There are no data on the presence of latanoprost bunod in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding must be considered along with the mother's potential clinical need for latanoprost bunod and any possible risk to the breastfed infant [FDA Label].&#13;
&#13;
Prolonged, continued use of latanoprost bunod 0.024% opthalmic solution is expected to cause increased pigmentation of the iris and eyelid. Such pigmentation is expected to increase for as long as the medication is used. Upon discontinuing the medication, although pigmentation changes of the eyelid tissue may likely reverse, pigmentation changes to the iris is likely permanent. Such pigmentation changes typically present as brown pigmentation spreading and increasing concentrically outward from the pupil. These changes may not be noticeable for several months to years. The long-term effects of increased pigmentation are not known and any prospective patients should be informed of this effect. While usage of the medication can continue in patients who do develop such pigmentation changes they should also be examined regularly [FDA Label].&#13;
&#13;
Prolonged, continued use of this medication is also expected to cause changes involving the increased length, thickness, and number of eyelash hairs. These changes are usually reversible upon discontinuation of the medication.&#13;
&#13;
Latanoprost bunod can cause or exacerbate existing intraocular inflammation (iritis or uveitis). Use with caution in patients with a history of or active intraocular inflammation.&#13;
&#13;
As a prostaglanding analog, latanoprost bunod has the potential to cuase macular edema, including cystoid macular edema. Use with caution in aphakic patients, in pseudoaphakic patients with a torn posterior lens capsule, or in patients with with known risk factors for macular edema.&#13;
&#13;
Bacterial keratitis or other eye infections are commonly associated with the use of opthalmic solution containers that have been inadvertently contaminated by patients who have a concurrent corneal disease or a disruption of the ocular epithelial surfaced.&#13;
&#13;
Contact lenses should be removed prior to the use of latanoprost bunod because its benzalkonium chloride preservative can affect or alter contact lenses [FDA Label].&#13;
&#13;
The most common adverse reactions obseved in patients treated with latanoprostene bunod during clinical trials were conjuctival hyperemica, eye irritation, eye pain, and installation site pain [FDA Lable].</toxicity>
  <metabolism>Upon topical administration at the ocular surface, latanoprostene bunod undergoes rapid carboxyl ester hydrolysis by endogenous corneal esterases into latanoprost acid and butanediol mononitrate [FDA Label].&#13;
&#13;
After the latanoprost acid reaches the systemic circulation, it is largely metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites by way of fatty acid beta-oxidation [FDA Label].&#13;
&#13;
The butanediol monohidrate undergoes further metabolism (reduction) to 1,4-butanediol and nitric oxide (NO). Furthermore, this 1,4-butanediol metabolite is further oxidized to succinic acid that is subsequently then primarily taken up as a component in the tricarboxylic acid (TCA) cycle in cellular aerobic respiration [FDA Label].</metabolism>
  <absorption>In a study with 22 healthy subjects monitored for 28 days, there were no quantifiable plasma concentrations of latanoprostene bunod (Lower Limit Of Quantitation, LLOQ, of 10.0 pg/mL) or butanediol mononitrate (LLOQ of 200 pg/mL) post daily dose of one drop bilaterally in the morning on Day 1 and 28 [FDA Label].&#13;
&#13;
The mean time of maximum plasma concentration (Tmax) for latanoprost acid was about 5 minutes post dosage on both Day 1 and 28 of therapy [FDA Label].&#13;
&#13;
The mean maximum plasma concentrations (Cmax) of latanoprost acid (LLOQ of 30 pg/mL) were 59.1 pg/mL on Day 1 and 28, respectively [FDA Label]. </absorption>
  <half-life>The half-life after application of latanoprostene bunod in rabbits was 1.8 hours in cornea, 2.1 hours in aqueous humor, and 4.6 hours in the iris/ciliary body [A31285].</half-life>
  <protein-binding/>
  <route-of-elimination>The latanoprost acid component of latanoprostene bunod is predominantly metabolized by the liver and excreted primarily in the urine [FDA Label].</route-of-elimination>
  <volume-of-distribution>Unfortunately there have been no formal ocular distribution studies performed in humans at this time [FDA Label].</volume-of-distribution>
  <clearance>Since latanoprost acid plasma concentration dropped below the LLOQ (Lower Limit Of Quantitation) of 30 pg/mL in the majority of study subjects by 15 minutes following ordinary ocular administration, the elimination of latanoprost acid from human plasma is considered rapid [FDA Label].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.</description>
    <direct-parent>Prostaglandins and related compounds</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Fatty Acyls</class>
    <subclass>Eicosanoids</subclass>
    <alternative-parent>Alkyl nitrates</alternative-parent>
    <alternative-parent>Benzene and substituted derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Cyclopentanols</alternative-parent>
    <alternative-parent>Fatty acid esters</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic nitric acids and derivatives</alternative-parent>
    <alternative-parent>Organic nitro compounds</alternative-parent>
    <alternative-parent>Organic nitrogen compounds</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Alkyl nitrate</substituent>
    <substituent>Allyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Cyclopentanol</substituent>
    <substituent>Fatty acid ester</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrate</substituent>
    <substituent>Organic nitric acid or derivatives</substituent>
    <substituent>Organic nitro compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Prostaglandin skeleton</substituent>
    <substituent>Secondary alcohol</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn/usan">Latanoprostene bunod</synonym>
  </synonyms>
  <products>
    <product>
      <name>Vyzulta</name>
      <labeller>Bausch &amp; Lomb Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484218</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.024 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vyzulta</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>0.24 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA207795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Vyzulta</name>
      <ingredients>Latanoprostene bunod</ingredients>
    </mixture>
    <mixture>
      <name>Vyzulta</name>
      <ingredients>Latanoprostene bunod</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Autacoids</category>
      <mesh-id>D012898</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Drugs that are Mainly Renally Excreted</category>
      <mesh-id/>
    </category>
    <category>
      <category>Eicosanoids</category>
      <mesh-id>D015777</mesh-id>
    </category>
    <category>
      <category>Fatty Acids</category>
      <mesh-id>D005227</mesh-id>
    </category>
    <category>
      <category>Fatty Acids, Unsaturated</category>
      <mesh-id>D005231</mesh-id>
    </category>
    <category>
      <category>Inflammation Mediators</category>
      <mesh-id>D018836</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Prostaglandin analogs reducing intraocular pressure (IOP)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Prostaglandins</category>
      <mesh-id>D011453</mesh-id>
    </category>
    <category>
      <category>Prostaglandins, Synthetic</category>
      <mesh-id>D011465</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength>0.024 %</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength>0.24 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>52:40.28</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11660.pdf?1510872933</fda-label>
  <patents>
    <patent>
      <number>8058467</number>
      <country>United States</country>
      <approved>2011-11-15</approved>
      <expires>2025-01-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7910767</number>
      <country>United States</country>
      <approved>2011-03-22</approved>
      <expires>2025-01-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7273946</number>
      <country>United States</country>
      <approved>2007-09-25</approved>
      <expires>2025-10-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7629345</number>
      <country>United States</country>
      <approved>2009-12-08</approved>
      <expires>2025-01-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6211233</number>
      <country>United States</country>
      <approved>2001-04-03</approved>
      <expires>2018-06-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Licofelone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Polmacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Flurbiprofen axetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00905</drugbank-id>
      <name>Bimatoprost</name>
      <description>The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Latanoprostene bunod.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.94</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.20e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.79</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-(nitrooxy)butyl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>4-(nitrooxy)butyl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>507.624</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>507.283217284</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C27H41NO8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LOVMMUBRQUFEAH-UIEAZXIASA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>139.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>136.66</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>56.95</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>23032</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>11156438</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347828030</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>9331546</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Latanoprostene_bunod</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2364612</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11660</drugbank-id>
        <name>Latanoprostene bunod</name>
      </left-element>
      <right-element>
        <drugbank-id>DB00654</drugbank-id>
        <name>Latanoprost</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0004740</drugbank-id>
          <name>Carboxylesterase</name>
          <uniprot-id>Q6LAP9</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11660</drugbank-id>
        <name>Latanoprostene bunod</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02011</drugbank-id>
        <name>Butanediol mononitrate</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0004740</drugbank-id>
          <name>Carboxylesterase</name>
          <uniprot-id>Q6LAP9</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02011</drugbank-id>
        <name>Butanediol mononitrate</name>
      </left-element>
      <right-element>
        <drugbank-id>DB01955</drugbank-id>
        <name>1,4-Butanediol</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002281</drugbank-id>
          <name>Glutathione S-transferase A1</name>
          <uniprot-id>P08263</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02011</drugbank-id>
        <name>Butanediol mononitrate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01480</drugbank-id>
        <name>Nitric Oxide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002281</drugbank-id>
          <name>Glutathione S-transferase A1</name>
          <uniprot-id>P08263</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB00654</drugbank-id>
        <name>Latanoprost</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02014</drugbank-id>
        <name>1,2 dinor latanoprost acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0001745</drugbank-id>
          <name>Medium-chain specific acyl-CoA dehydrogenase, mitochondrial</name>
          <uniprot-id>P11310</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0004521</drugbank-id>
          <name>3-ketoacyl-CoA thiolase, peroxisomal</name>
          <uniprot-id>P09110</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0004500</drugbank-id>
          <name>Enoyl-CoA hydratase, mitochondrial</name>
          <uniprot-id>P30084</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000377</drugbank-id>
          <name>Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial</name>
          <uniprot-id>Q16836</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB00654</drugbank-id>
        <name>Latanoprost</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02015</drugbank-id>
        <name>1,2,3,4-tetranor latanoprost acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0001745</drugbank-id>
          <name>Medium-chain specific acyl-CoA dehydrogenase, mitochondrial</name>
          <uniprot-id>P11310</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0004521</drugbank-id>
          <name>3-ketoacyl-CoA thiolase, peroxisomal</name>
          <uniprot-id>P09110</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0004500</drugbank-id>
          <name>Enoyl-CoA hydratase, mitochondrial</name>
          <uniprot-id>P30084</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000377</drugbank-id>
          <name>Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial</name>
          <uniprot-id>Q16836</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DB01955</drugbank-id>
        <name>1,4-Butanediol</name>
      </left-element>
      <right-element>
        <drugbank-id>DB01440</drugbank-id>
        <name>gamma-Hydroxybutyric acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0000227</drugbank-id>
          <name>Alcohol dehydrogenase 1A</name>
          <uniprot-id>P07327</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000400</drugbank-id>
          <name>Alcohol dehydrogenase 1B</name>
          <uniprot-id>P00325</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000465</drugbank-id>
          <name>Alcohol dehydrogenase 1C</name>
          <uniprot-id>P00326</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>4</sequence>
      <left-element>
        <drugbank-id>DB01440</drugbank-id>
        <name>gamma-Hydroxybutyric acid</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01477</drugbank-id>
        <name>Succinic Acid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0000227</drugbank-id>
          <name>Alcohol dehydrogenase 1A</name>
          <uniprot-id>P07327</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000400</drugbank-id>
          <name>Alcohol dehydrogenase 1B</name>
          <uniprot-id>P00325</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0000465</drugbank-id>
          <name>Alcohol dehydrogenase 1C</name>
          <uniprot-id>P00326</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000610</id>
      <name>Prostaglandin F2-alpha receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P43088" source="Swiss-Prot">
        <name>Prostaglandin F2-alpha receptor</name>
        <general-function>Prostaglandin f receptor activity</general-function>
        <specific-function>Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost.</specific-function>
        <gene-name>PTGFR</gene-name>
        <locus>1p31.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>32-54
70-90
110-131
153-175
199-224
251-267
286-307</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.11</theoretical-pi>
        <molecular-weight>40054.1</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9600</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTGFR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L24470</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>456564</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P43088</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PF2R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PGF receptor</synonym>
          <synonym>Prostanoid FP receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001217|Prostaglandin F2-alpha receptor
MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQ
KSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGL
CPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQ
ASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQG
RSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILD
PWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016151|Prostaglandin F2-alpha receptor (PTGFR)
ATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCTGCAGCTGCGCTTCTTTCAAACACA
ACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTAATCTTCATGACAGTGGGA
ATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCATATCAGAGATTTAGACAG
AAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTAATCACTGATTTCTTTGGC
CATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCTGATAAAGAATGGATCCGC
TTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGCATGGTGTTTTCTGGTCTG
TGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCA
ATATTTCATTCTACGAAAATTACATCCAAACATGTGAAAATGATGTTAAGTGGTGTGTGC
TTGTTTGCTGTTTTCATAGCTTTGCTGCCCATCCTTGGACATCGAGACTATAAAATTCAG
GCGTCGAGGACCTGGTGTTTCTACAACACAGAAGACATCAAAGACTGGGAAGATAGATTT
TATCTTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTTCATTGTTGTGCAAT
GCAATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGTCAGCAGCACAGACAAGGC
AGATCTCATCATTTGGAAATGGTAATCCAGCTCCTGGCGATAATGTGTGTCTCCTGTATT
TGTTGGAGCCCATTTCTGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTG
GAAACCTGTGAAACAACACTTTTTGCTCTCCGAATGGCAACATGGAATCAAATCTTAGAT
CCTTGGGTATATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAGCTTGCCAGT
CAATGCTGTGGAGTGCATGTCATCAGCTTACATATTTGGGAGCTTAGTTCCATTAAAAAT
TCCTTAAAGGTTGCTGCTATTTCTGAGTCACCAGTTGCAGAGAAATCAGCAAGCACCTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin F receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling using intracellular calcium source</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to prostaglandin D stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>parturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="2">
      <id>BE0001042</id>
      <name>Solute carrier organic anion transporter family member 2B1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16435</ref-id>
            <pubmed-id>20019365</pubmed-id>
            <citation>Kraft ME, Glaeser H, Mandery K, Konig J, Auge D, Fromm MF, Schlotzer-Schrehardt U, Welge-Lussen U, Kruse FE, Zolk O: The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. doi: 10.1167/iovs.09-4290. Epub 2009 Dec 17.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O94956" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 2B1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.</specific-function>
        <gene-name>SLCO2B1</gene-name>
        <locus>11q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>50-69
89-109
116-140
186-215
235-255
274-298
367-388
409-432
437-460
565-587
597-622
656-673</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.39</theoretical-pi>
        <molecular-weight>76709.98</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10962</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLCO2B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB026256</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5006263</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O94956</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO2B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>KIAA0880</synonym>
          <synonym>OATP-B</synonym>
          <synonym>OATP-RP2</synonym>
          <synonym>OATP2B1</synonym>
          <synonym>OATPB</synonym>
          <synonym>OATPRP2</synonym>
          <synonym>Organic anion transporter B</synonym>
          <synonym>Organic anion transporter polypeptide-related protein 2</synonym>
          <synonym>SLC21A9</synonym>
          <synonym>Solute carrier family 21 member 9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037115|Solute carrier organic anion transporter family member 2B1
MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKLFVLCHSLLQL
AQLMISGYLKSSISTVEKRFGLSSQTSGLLASFNEVGNTALIVFVSYFGSRVHRPRMIGY
GAILVALAGLLMTLPHFISEPYRYDNTSPEDMPQDFKASLCLPTTSAPASAPSNGNCSSY
TETQHLSVVGIMFVAQTLLGVGGVPIQPFGISYIDDFAHNSNSPLYLGILFAVTMMGPGL
AFGLGSLMLRLYVDINQMPEGGISLTIKDPRWVGAWWLGFLIAAGAVALAAIPYFFFPKE
MPKEKRELQFRRKVLAVTDSPARKGKDSPSKQSPGESTKKQDGLVQIAPNLTVIQFIKVF
PRVLLQTLRHPIFLLVVLSQVCLSSMAAGMAIFLPKFLERQFSITASYANLLIGCLSFPS
VIVGIVVGGVLVKRLHLGPVGCGALCLLGMLLCLFFSLPLFFIGCSSHQIAGITHQTSAH
PGLELSPSCMEACSCPLDGFNPVCDPSTRVEYITPCHAGCSSWVVQDALDNSQVFYTNCS
CVVEGNPVLAGSCDSTCSHLVVPFLLLVSLGSALACLTHTPSFMLILRGVKKEDKTLAVG
IQFMFLRILAWMPSPVIHGSAIDTTCVHWALSCGRRAVCRYYNNDLLRNRFIGLQFFFKT
GSVICFALVLAVLRQQDKEARTKESRSSPAVEQQLLVSGPGKKPEDSRV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010728|Solute carrier organic anion transporter family member 2B1 (SLCO2B1)
ATGGGCACAGAAAACACACCTGGAGGCAAAGCCAGCCCAGACCCTCAGGACGTGCGGCCA
AGTGTGTTCCATAACATCAAGCTGTTCGTTCTGTGCCACAGCCTGCTGCAGCTGGCGCAG
CTCATGATCTCCGGCTACCTAAAGAGCTCCATCTCCACAGTGGAGAAGCGCTTCGGCCTC
TCCAGCCAGACGTCGGGGCTGCTGGCCTCCTTCAACGAGGTGGGGAACACAGCCTTGATT
GTGTTTGTGAGCTATTTTGGCAGCCGGGTGCACCGACCCCGAATGATTGGCTATGGGGCT
ATCCTTGTGGCCCTGGCGGGCCTGCTCATGACTCTCCCGCACTTCATCTCGGAGCCATAC
CGCTACGACAACACCAGCCCTGAGGATATGCCACAGGACTTCAAGGCTTCCCTGTGCCTG
CCCACAACCTCGGCCCCAGCCTCGGCCCCCTCCAATGGCAACTGCTCAAGCTACACAGAA
ACCCAGCATCTGAGTGTGGTGGGGATCATGTTCGTGGCACAGACCCTGCTGGGCGTGGGC
GGGGTGCCCATTCAGCCCTTTGGCATCTCCTACATCGATGACTTTGCCCACAACAGCAAC
TCGCCCCTCTACCTCGGGATCCTGTTTGCAGTGACCATGATGGGGCCAGGCCTGGCCTTT
GGGCTGGGCAGCCTCATGCTGCGCCTTTATGTGGACATTAACCAGATGCCAGAAGGTGGT
ATCAGCCTGACCATAAAGGACCCCCGATGGGTGGGTGCCTGGTGGCTGGGTTTCCTCATC
GCTGCCGGTGCAGTGGCCCTGGCTGCCATCCCCTACTTCTTCTTCCCCAAGGAAATGCCC
AAGGAAAAACGTGAGCTTCAGTTTCGGCGAAAGGTCTTAGCAGTCACAGACTCACCTGCC
AGGAAGGGCAAGGACTCTCCCTCTAAGCAGAGCCCTGGGGAGTCCACGAAGAAGCAGGAT
GGCCTAGTCCAGATTGCACCAAACCTGACTGTGATCCAGTTCATTAAAGTCTTCCCCAGG
GTGCTGCTGCAGACCCTACGCCACCCCATCTTCCTGCTGGTGGTCCTGTCCCAGGTATGC
TTGTCATCCATGGCTGCGGGCATGGCCACCTTCCTGCCCAAGTTCCTGGAGCGCCAGTTT
TCCATCACAGCCTCCTACGCCAACCTGCTCATCGGCTGCCTCTCCTTCCCTTCGGTCATC
GTGGGCATCGTGGTGGGTGGCGTCCTGGTCAAGCGGCTCCACCTGGGCCCTGTGGGATGC
GGTGCCCTTTGCCTGCTGGGGATGCTGCTGTGCCTCTTCTTCAGCCTGCCGCTCTTCTTT
ATCGGCTGCTCCAGCCACCAGATTGCGGGCATCACACACCAGACCAGTGCCCACCCTGGG
CTGGAGCTGTCTCCAAGCTGCATGGAGGCCTGCTCCTGCCCATTGGACGGCTTTAACCCT
GTCTGCGACCCCAGCACTCGTGTGGAATACATCACACCCTGCCACGCAGGCTGCTCAAGC
TGGGTGGTCCAGGATGCTCTGGACAACAGCCAGGTTTTCTACACCAACTGCAGCTGCGTG
GTGGAGGGCAACCCCGTGCTGGCAGGATCCTGCGACTCAACGTGCAGCCATCTGGTGGTG
CCCTTCCTGCTCCTGGTCAGCCTGGGCTCGGCCCTGGCCTGTCTCACCCACACACCCTCC
TTCATGCTCATCCTAAGAGGAGTGAAGAAAGAAGACAAGACTTTGGCTGTGGGCATCCAG
TTCATGTTCCTGAGGATTTTGGCCTGGATGCCCAGCCCCGTGATCCACGGCAGCGCCATC
GACACCACCTGTGTGCACTGGGCCCTGAGCTGTGGGCGTCGAGCTGTCTGTCGCTACTAC
AATAATGACCTGCTCCGAAACCGGTTCATCGGCCTCCAGTTCTTCTTCAAAACAGGTTCT
GTGATCTGCTTCGCCTTAGTTTTGGCTGTCCTGAGGCAGCAGGACAAAGAGGCAAGGACC
AAAGAGAGCAGATCCAGCCCTGCCGTAGAGCAGCAATTGCTAGTGTCGGGGCCAGGGAAG
AAGCCAGAGGATTCCCGAGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>